Which radioactive drug hits tumors harder? small study aims to find out
NCT ID NCT06516510
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study compared two radioactive drugs, lutetium rhPSMA-10.1 and Pluvicto, in 17 men with metastatic prostate cancer that cannot be cured. The goal was to see which drug delivers more radiation to tumors and less to healthy organs like the kidneys. The study was terminated early, so findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
What this could lead to
If successful, this could help identify which drug is better at targeting tumors while sparing healthy organs, potentially improving future treatment choices.
What could go wrong
This was a very early, small study (17 people) that was terminated, so results are limited and may not apply to all patients. No treatment benefit was directly tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biogenix Molecular LLC
Miami, Florida, 33165, United States
-
Centro Integral Oncologico Clara Campal
Madrid, Madrid, 28050, Spain
-
Clinica Universidad de Navarra
Madrid, 28027, Spain
-
Clinica Universidad de Navarra - Pamplona
Pamplona, Navarre, 31008, Spain
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
Radboud UMC
Nijmegen, Gelderland, 6525GA, Netherlands